Rejoni published the pivotal trial behind its Juveena Hydrogel System in Fertility and Sterility and presented it on November 13 at the AAGL global congress in Boston. FDA granted the device premarket approval under P250051 in September 2026, for reducing the incidence and severity of intrauterine adhesions after hysteroscopic adhesiolysis in adult women with symptomatic moderate-to-severe adhesions.

The trial randomized 150 patients 2:1 at 15 US academic and community centers, 99 to the hydrogel and 51 to no barrier. A blinded independent committee reviewed paired video from second-look hysteroscopy to score the primary endpoint. In the adhesiolysis subgroup, 60.3 percent of hydrogel patients were adhesion-free against 32.3 percent of controls (odds ratio 3.19, 95 percent CI 1.29 to 7.90, p=0.015). Severe adhesions appeared in 6.3 percent versus 32.3 percent (odds ratio 0.14, 95 percent CI 0.04 to 0.50, p=0.002). Device-related adverse events occurred in 8 percent of Juveena patients, all non-serious per the company.

Juveena delivers two polymer solutions through a transcervical catheter that form a hydrogel in place. Rejoni, based in Burlington, Massachusetts, was founded in June 2020 by Amar Sawhney, who also started Confluent Surgical, Ocular Therapeutix and Augmenix. CEO John Nealon said the congress draws the surgeons who manage these adhesions daily.

The blinded central review of paired video is the part to copy. A PMA endpoint read by the treating surgeon invites questions FDA will ask anyway, and paying for independent adjudication up front is cheaper than answering them in a deficiency letter.